Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease-Reference-Cited by-同舟云学术

Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease

Published:2021-02-12 Issue:6 Volume:100 Page:e24731
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Komaki Yuga,Kanmura Shuji,Yutsudo Kazuki,Kuwazuru Kosuke,Komaki Fukiko,Tanaka Akihito,Nishimata Nobuaki,Sameshima Yoichi,Sasaki Fumisato,Ohi Hidehisa,Nakamura Yuichi,Tokushige Koichi,Sameshima Yukinori,Ido Akio

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference39 articles.

1. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease;Sakuraba;Gastroenterology,2009

2. Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease;Sato;Gastroenterology,2004

3. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

4. Combined modality treatment for complex fistulating perianal Crohn's disease;Antakia;Colorectal Dis,2013

5. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease;Drobne;Aliment Pharmacol Ther,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review;Advances in Therapy;2023-03-17

2. Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021;Journal of Gastroenterology;2023-02-11